These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29307843)

  • 1. Development of leads targeting ER-α in breast cancer: An in silico exploration from natural domain.
    Ashtekar SS; Bhatia NM; Bhatia MS
    Steroids; 2018 Mar; 131():14-22. PubMed ID: 29307843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
    Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
    J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
    Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
    Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, and
    Choudhari RC; Kaur K; Das A; Jaitak V
    Curr Comput Aided Drug Des; 2024; 20(5):640-652. PubMed ID: 37888813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
    Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
    Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular docking and ¬in-silico study of natural antagonists of ER-alpha receptor: Potential candidates against breast cancer.
    Ahmed B; Qadir MI; Noor-Ul-Ain H
    Pak J Pharm Sci; 2020 Mar; 33(2):733-738. PubMed ID: 32276920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico identification of novel inhibitors targeting the DNA-binding domain of the human estrogen receptor alpha.
    Cao H; Sun Y; Wang L; Pan Y; Li Z; Liang Y
    J Steroid Biochem Mol Biol; 2021 Oct; 213():105966. PubMed ID: 34416373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of estrogen receptor α ligands with virtual screening techniques.
    Niinivehmas SP; Manivannan E; Rauhamäki S; Huuskonen J; Pentikäinen OT
    J Mol Graph Model; 2016 Mar; 64():30-39. PubMed ID: 26774287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
    Chaudhari P; Bari S
    Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding capacity of ER-α ligands and SERMs: comparison of the human, dog and cat.
    Toniti W; Suthiyotha N; Puchadapirom P; Jenwitheesuk E
    Asian Pac J Cancer Prev; 2011; 12(11):2875-9. PubMed ID: 22393957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Estrogen Receptor
    Pang X; Fu W; Wang J; Kang D; Xu L; Zhao Y; Liu AL; Du GH
    Oxid Med Cell Longev; 2018; 2018():6040149. PubMed ID: 29861831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANN-QSAR model for virtual screening of androstenedione C-skeleton containing phytomolecules and analogues for cytotoxic activity against human breast cancer cell line MCF-7.
    Prakash O; Khan F; Sangwan RS; Misra L
    Comb Chem High Throughput Screen; 2013 Jan; 16(1):57-72. PubMed ID: 23030276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multitargeted Molecular Docking Study of Natural-Derived Alkaloids on Breast Cancer Pathway Components.
    Singla R; Jaitak V
    Curr Comput Aided Drug Des; 2017 Nov; 13(4):294-302. PubMed ID: 28382865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer.
    Makar S; Saha T; Swetha R; Gutti G; Kumar A; Singh SK
    Bioorg Chem; 2020 Jan; 94():103380. PubMed ID: 31757413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
    Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
    Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking, QSAR, pharmacophore modeling, and dynamics studies of some chromone derivatives for the discovery of anti-breast cancer agents against hormone-dependent breast cancer.
    Arvindekar SA; Mohole S; Patil A; Mane P; Arvindekar A; Mali SN; Thorat B; Rawat R; Sharma S
    J Biomol Struct Dyn; 2023; 41(24):14757-14770. PubMed ID: 36995997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
    Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor.
    Khalid S; Hanif R; Jabeen I; Mansoor Q; Ismail M
    PLoS One; 2018; 13(5):e0196312. PubMed ID: 29787591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico docking studies of selected flavonoids--natural healing agents against breast cancer.
    Suganya J; Radha M; Naorem DL; Nishandhini M
    Asian Pac J Cancer Prev; 2014; 15(19):8155-9. PubMed ID: 25338999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.